7-year review long run after the approved production of Zhifei biological AC Hib triple vaccine

The AC Hib triple vaccine independently developed by Beijing green bamboo, a wholly-owned subsidiary of Zhifei biology, was finally approved for production after a seven-year review run It is reported that in the second half of last year, the company has begun to plan and preheat the marketing and promotion of the vaccine According to the website of the State Food and Drug Administration (CFDA) on April 4, the review status of "AC group meningococcal Haemophilus influenzae polysaccharide conjugate vaccine" (i.e AC Hib triple vaccine) in Beijing green bamboo changed to "approval completed - to be prepared certificate", with the state drug approval No s20140003, and the company is expected to obtain the production approval document in the near future In mid December 2013, the head of Zhifei biology said at a strategic meeting of a securities firm that AC Hib triple vaccine is an upgraded product of Hib vaccine and AC group meningitis vaccine, which can prevent related diseases caused by group A, group C meningococci and Haemophilus influenzae type B at the same time, so as to reduce the number of vaccinations The market price of the vaccine will not be less than 180 yuan / piece, and the market capacity is expected to be about 68 million pieces, with a high prospect The vaccine is also a heavy-duty vaccine product that the company has high hopes for.